Prostate Cancer And Agent Orange Is Not The Only Military Concern

Agent Orange is usually the first thing veterans with prostate cancer ask about.   Indeed, way back in 1998, Malecare was an early advocate for men exposed to Agent Orange. Military veterans as well as Vietnamese, Cambodian and Laotian civilians were exposed to Agent Orange, and many of those who are men are now diagnosed, [...]

By |2018-05-27T23:55:25-04:00May 25th, 2018|Advanced Prostate Cancer, Advocacy, Research|3 Comments

Apalutamide Looking Good as Treatment for Non-Metastatic Castrate Resistant Prostate Cancer

Non-Metastatic Castrate Resistant Prostate Cancer (nmCRPC)  usually leads to metastatic prostate cancer and death. There are no approved treatments for nmCRPC. Apalutamide is a taken-by-mouth androgen receptor inhibitor with antitumor activity in CRPC. There's a much talked and written about clinical trial called, SPARTAN, that investigated how well Apalutamide works on maintaining metastasis-free survival (MFS) [...]

Cancer Diagnosis Causes Increased Emotional Problems for Too Many of Us

Being diagnosed with cancer is tough. Being diagnosed with cancer is often coupled with clinically meaningful levels of mental or emotional distress. Researchers in Germany have found that during the prior four weeks nearly a third of more than 2,100 cancer survivors interviewed at inpatient and outpatient care centers experienced mental or emotional distress that [...]

The House Passes The 21st Century Cures Act – On To The Senate

Last Wednesday the House passed with a vote of 392 to 26, a medical innovation bill known as the 21st Century Cures Act, aimed at curing diseases, with the measure securing bipartisan support after months of negotiations. The bill’s goals are to speed up the Food and Drug Administration’s approval of new drugs while also investing [...]

Politics As Usual As Congress Prepares To Not Pass The Budget – A Potential Devastating Problem for Medical Research

It is deeply troubling  to learn that Congress is considering not completing the fiscal year 2017 budget appropriations process.  Because of the normal political fighting that we still see in Washington, Congress is now considering passing a short-term or even long-term budget continuing resolution instead of the negotiated budget resolution they have worked so hard [...]

Vitamin D3 Potentiates Metformin in DU145 Human Prostate Cancer Cells

It is well established that common drugs like Metformin and vitamin D? exhibit a strong anti-proliferative action in many cancer cell lines. Recent research confirms that this is also true in human prostate cancer cells. In a recent study it was demonstrated that the combination of the two drugs, metformin and vitamin D3, had a [...]

To Debulk Or Not To Debulk, That Is The Question

You have been diagnosed with advanced or metastatic prostate cancer. It is a shock, you have cancer and your cancer has already spread outside of the prostate gland. Your doctor might have already told you that at this stage it is no longer curable, and technically it can be called terminal! That is a lot [...]

Understanding the Risk Factors for Hereditary Prostate Cancer – A Surprise

We often refer to prostate cancer as a family affair, or rather being passed on from father to son, etc. This is only partially true because there is still more prostate cancer diagnosed in men without any family history. For those cancers that are passed on from one family member to another it is important [...]

Good News, The House Appropriations Committee Increases the Ask For The DoD PCRP Allocation for FY 2017

Today, I have some good news to share with you. Malecare, along with many other prostate cancer advocacy groups have been hard at work attempting to persuade members of Congress to not only maintain the Department of Defense Prostate Cancer Research Program (DoD PCRP), but to increase its funding for the next fiscal year. I [...]

An Independent Prognostic Tool For Men With Metastatic Castrate Resistant Prostate Cancer Taking The Newer Drugs

We have a number of newer hormone pathway drugs now available to treat men with metastatic castrate resistant prostate cancer (mCRPC). Researchers have shown that prostate specific antigen (PSA) response can be used as a pharmaco-dynamic end-point that may help identify men with early resistance to these new drugs. They found that there is clinical [...]

Go to Top